Leveraging Neuroimaging Tools to Assess Precision and Accuracy in an Alzheimer's Disease Neuropathologic Sampling Protocol

被引:1
|
作者
Webster, Jason M. [1 ]
Grabowski, Thomas J. [1 ,2 ]
Madhyastha, Tara M. [1 ]
Gibbons, Laura E. [3 ]
Keene, C. Dirk [4 ]
Latimer, Caitlin S. [4 ]
机构
[1] Univ Washington, Dept Radiol, Seattle, WA USA
[2] Univ Washington, Dept Neurol, Seattle, WA USA
[3] Univ Washington, Dept Med, Seattle, WA USA
[4] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
关键词
Alzheimer's disease; neuropathology; neuroimaging; functional connectivity; accuracy; precision; ASSOCIATION GUIDELINES; NATIONAL INSTITUTE; DEFINED SUBTYPES; REGISTRATION; ROBUST; OPTIMIZATION;
D O I
10.3389/fnins.2021.693242
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction: The study of Alzheimer's disease investigates topographic patterns of degeneration in the context of connected networks comprised of functionally distinct domains using increasingly sophisticated molecular techniques. Therefore, obtaining high precision and accuracy of neuropathologic tissue sampling will enhance the reliability of molecular studies and contribute to the understanding of Alzheimer's disease pathology. Neuroimaging tools can help assess these aspects of current sampling protocols as well as contribute directly to their improvement. Methods: Using a virtual sampling method on magnetic resonance images (MRIs) from 35 participants (21 women), we compared the precision and accuracy of traditional neuropathologic vs. neuroimaging-guided sampling. The impact of the resulting differences was assessed by evaluating the functional connectivity pattern of regions selected by each approach. Results: Virtual sampling using the traditional neuropathologic approach had low neuroanatomical precision and accuracy for all cortical regions tested. Neuroimaging-guided strategies narrowed these gaps. Discrepancies in the location of traditional and neuroimaging-guided samples corresponded to differences in fMRI measures of functional connectivity. Discussion: Integrating neuroimaging tools with the neuropathologic assessment will improve neuropathologic-neuroimaging correlations by helping to ensure specific functional domains are accurately sampled for quantitative molecular neuropathologic applications. Our neuroimaging-based simulation of current sampling practices provides a benchmark of precision and accuracy against which to measure improvements when using novel tissue sampling approaches. Our results suggest that relying on gross landmarks alone to select samples at autopsy leads to significant variability, even when sampled by the same neuropathologist. Further, this exercise highlights how sampling precision could be enhanced if neuroimaging were integrated with the standard neuropathologic assessment. More accurate targeting and improved biological homogeneity of sampled brain tissue will facilitate the interpretation of neuropathological analyses in AD and the downstream research applications of brain tissue from biorepositories.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Alzheimer's disease neurodegeneration markers in Alzheimer's disease neuroimaging initiative
    Andriuta, D.
    Moullart, V.
    Schraen, S.
    Meyer, M. -E.
    Godefroy, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 93 - 93
  • [42] The Use of Neuroimaging to Assess Associations Among Diet, Nutrients, Metabolic Syndrome, and Alzheimer's Disease
    Pistollato, Francesca
    Sumalla Cano, Sandra
    Elio, Inaki
    Masias Vergara, Manuel
    Giampieri, Francesca
    Battino, Maurizio
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 48 (02) : 303 - 318
  • [43] Neuropathologic correlates of activities of daily living in Alzheimer's disease
    Marshall, GA
    Fairbanks, L
    Tekin, S
    Vinters, HV
    Cummings, JL
    NEUROLOGY, 2005, 64 (06) : A137 - A137
  • [44] No increased severity of neuropathologic features in Alzheimer's disease with psychosis
    Sweet, RA
    Hamilton, RL
    Lopez, OL
    Klunk, WE
    Wisniewski, SR
    DeKosky, ST
    BIOLOGICAL PSYCHIATRY, 2000, 47 (08) : 143S - 143S
  • [45] Amyloid-β predominant Alzheimer's disease neuropathologic change
    Kovacs, Gabor G.
    Katsumata, Yuriko
    Wu, Xian
    Aung, Khine Zin
    Fardo, David W.
    Forrest, Shelley L.
    Alzheimers Dis Genetics Consortium, James D.
    Nelson, Peter T.
    BRAIN, 2024, 148 (02) : 401 - 407
  • [46] Agreement between neuropathologic criteria for the diagnosis of Alzheimer's disease
    Zhang, Z
    Ramos, E
    Zhou, A
    Koepsell, T
    Kukull, WA
    NEUROLOGY, 2006, 66 (05) : 283 - 283
  • [47] Microscope field size and the neuropathologic criteria for Alzheimer's disease
    Petrovitch, H
    Nelson, J
    Snowdon, D
    Davis, DG
    Ross, GW
    Li, CY
    White, L
    NEUROLOGY, 1997, 49 (04) : 1175 - 1176
  • [48] The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
    Caroli, A.
    Frisoni, G. B.
    NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1263 - 1274
  • [49] Alzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease Foreword
    Thies, William H.
    ALZHEIMERS & DEMENTIA, 2015, 11 (07) : 727 - 729
  • [50] Neuropathologic changes in Alzheimer's disease: Potential targets for treatment
    Wenk, GL
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 : 3 - 7